865
Календарь FDA для американских компаний
$SRPT (76.02$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:16 MSK
Berenberg Bank Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Berenberg Bank analyst Zhiqiang Shu maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $94.00. The company's shares closed last Tuesday at $76.02. According to...
👉 Show more
$ARDX (0.728$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:16 MSK
Ardelyx (ARDX) Receives a Hold from Piper Sandler
In a report issued on February 28, Christopher Raymond from Piper Sandler maintained a Hold rating on Ardelyx (ARDX – Research Report), with a price target of $4.00. The company's shares closed last Tuesday at $0.73,...
👉 Show more
$ALBO (27.57$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:16 MSK
Wedbush Reiterates Their Buy Rating on Albireo Pharma (ALBO)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma (ALBO – Research Report) today and set a price target of $84.00. The company's shares closed last Tuesday at $27.57. According to TipRanks.com,...
👉 Show more
$BCYC (47.3$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:16 MSK
Needham Maintains a Buy Rating on Bicycle Therapeutics (BCYC)
In a report released today, Ami Fadia from Needham maintained a Buy rating on Bicycle Therapeutics (BCYC – Research Report), with a price target of $85.00. The company's shares closed last Tuesday at $47.30. According to...
👉 Show more
$CCXI (29.46$) $TARO (49.22$) $SRPT (76.02$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:15 MSK
Analysts Are Bullish on These Healthcare Stocks: ChemoCentryx (CCXI), Taro Pharmaceutical (TARO)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ChemoCentryx (CCXI – Research Report), Taro Pharmaceutical (TARO – Research Report) and Sarepta Therapeutics (SRPT – Research...
👉 Show more
$ABBV (147.79$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:15 MSK
AbbVie Strengthens Neuroscience Portfolio with Syndesi Acquisition
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) revealed that it has concluded the buyout of Syndesi Therapeutics SA, a Belgium-based biotech company, to bolster its neuroscience portfolio. As per the agreed terms,...
👉 Show more
$CERE (28.37$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:15 MSK
H.C. Wainwright Reiterates a Buy Rating on Cerevel Therapeutics Holdings (CERE)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Cerevel Therapeutics Holdings (CERE – Research Report), with a price target of $50.00. The company's shares closed last Tuesday at...
👉 Show more
$NVCT (6.81$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:15 MSK
H.C. Wainwright Initiates a Buy Rating on Nuvectis Pharma, Inc. (NVCT)
H.C. Wainwright analyst Joseph Pantginis initiated coverage with a Buy rating on Nuvectis Pharma, Inc. (NVCT – Research Report) today and set a price target of $14.00. The company's shares closed last Tuesday at $6.81.
👉 Show more
$KPTI (10.39$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:15 MSK
Karyopharm Therapeutics (KPTI) Gets a Buy Rating from H.C. Wainwright
E ratio….
👉 Show more
$ERIC (8.86$) $FSLR (75.62$) $JWN (19.54$) $CCXI (29.46$) $SOFI (11.2$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:15 MSK
These Stocks are the Biggest Pre-Market Movers on Wednesday
Losers page, we've identified the top 5 pre-market stock movers, as detailed below. 5 Biggest Movers American luxury department store chain Nordstrom, Inc. (JWN) was the biggest gainer in pre-market...
👉 Show more
👍 $BMY
🕒 ср, 2 мар. 2022 г., 14:42:47 MSK
Bristol-Myers price target raised to $65 from $60 at Wells Fargo
$MRK (76.33$) $PFE (45.74$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:39:04 MSK
Biden unveils new initiative to provide free COVID-19 pills to Americans
👉 Show more
👍 $AGEN
🕒 ср, 2 мар. 2022 г., 14:33:43 MSK
Agenus price target raised to $14 from $12 at H.C. Wainwright
$NVCT (6.81$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:33:22 MSK
HC Wainwright & Co. Initiates Coverage On Nuvectis Pharma with Buy Rating, Announces Price Target of $14
HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Nuvectis Pharma (NASDAQ:NVCT) with a Buy rating and announces Price Target of $14.
$OSH (21.63$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:32:23 MSK
SVB Leerink Maintains Market Perform on Oak Street Health, Raises Price Target to $23
SVB Leerink analyst Whit Mayo maintains Oak Street Health (NYSE:OSH) with a Market Perform and raises the price target from $17 to $23.
$XENE (31.76$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:16 MSK
Xenon (XENE) Gets a Buy Rating from Needham
E ratio of -19.54.
👉 Show more
$AXSM (30.98$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:16 MSK
Berenberg Bank Maintains Their Buy Rating on Axsome Therapeutics (AXSM)
In a report released today, Esther Hong from Berenberg Bank maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price target of $109.00. The company's shares closed last Tuesday at $30.98.
👉 Show more
$PTGX (26.25$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:16 MSK
Protagonist Therapeutics (PTGX) Received its Third Buy in a Row
After Leerink Partners and J.P. Morgan gave Protagonist Therapeutics (NASDAQ:PTGX) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Douglas Tsao reiterated a Buy rating...
👉 Show more
$BCYC (47.3$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:16 MSK
Bicycle Therapeutics (BCYC) Receives a Buy from H.C. Wainwright
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Bicycle Therapeutics (BCYC – Research Report), with a price target of $65.00. The company's shares closed last Tuesday at...
👉 Show more
$AKBA (2.15$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:15 MSK
H.C. Wainwright Reaffirms Their Buy Rating on Akebia Therapeutics (AKBA)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price target of $10.00. The company's shares closed last Tuesday at $2.15. According to...
👉 Show more
$RPTX (16.06$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:15 MSK
Berenberg Bank Thinks Repare Therapeutics' Stock is Going to Recover
Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on Repare Therapeutics (RPTX – Research Report) today and set a price target of $51.00. The company's shares closed last Tuesday at $16.06, close to its 52-week...
👉 Show more
$CRTX (4.41$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:15 MSK
H.C. Wainwright Thinks Cortexyme's Stock is Going to Recover
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Cortexyme (CRTX – Research Report), with a price target of $30.00. The company's shares closed last Tuesday at $4.41, close to its...
👉 Show more
$TGTX (10.29$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:15 MSK
H.C. Wainwright Thinks TG Therapeutics' Stock is Going to Recover
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TG Therapeutics (TGTX – Research Report), with a price target of $68.00. The company's shares closed last Tuesday at $10.29, close...
👉 Show more
$EPZM (1.59$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:15 MSK
H.C. Wainwright Thinks Epizyme's Stock is Going to Recover
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Epizyme (EPZM – Research Report), with a price target of $10.00. The company's shares closed last Tuesday at $1.59, close to its...
👉 Show more
$ANNX (4.73$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:44:15 MSK
H.C. Wainwright Thinks Annexon Biosciences' Stock is Going to Recover
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Annexon Biosciences (ANNX – Research Report), with a price target of $40.00. The company's shares closed last Tuesday at $4.73,...
👉 Show more
$FWBI (1.18$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:40:09 MSK
First Wave BioPharma's Fast-Tracked Phase 2 Candidate To Treat COVID-RELATED GI Tract Infection Gives Hope To Millions (NASDAQ: FWBI)
Exploiting a valuation disconnect can be rewarding for investors. And First Wave BioPharma (NASDAQ:FWBI) presents one that’s too big to ignore. In fact, FWBI’s current share price is a textbook example of...
$EPZM (1.59$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:35:19 MSK
HC Wainwright & Co. Maintains Buy on Epizyme, Lowers Price Target to $10
HC Wainwright & Co. analyst Andrew Fein maintains Epizyme (NASDAQ:EPZM) with a Buy and lowers the price target from $15 to $10.
👍 $MRTX $AMGN
🕒 ср, 2 мар. 2022 г., 14:32:48 MSK
Mirati Therapeutics price target lowered to $227 from $244 at Citi
$CDXC (2.79$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:33:00 MSK
ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson's Disease (PD)
New Phase I research showcases NR supplementation significantly increased cerebral NAD levels, and decreased levels of inflammatory cytokines in Parkinson's disease (PD) patients ChromaDex Corp. (NASDAQ:CDXC) today...
$NUVL (14.89$)
🇺🇸 🕒 ср, 2 мар. 2022 г., 14:30:04 MSK
Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference
CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced...